While this suggests that the use of [18F]AV-1451 to select tau-mediated frontotemporal dementia populations for clinical trials is unlikely to be effective, the ligand may still retain a potential role in the longitudinal assessment of the degree and distribution of pathological burden across the frontotemporal dementia spectrum. This evidence concerns the gene MAPT and frontotemporal dementia.